CytoDyn to Hold Conference Call on September 16 to Provide Update on Discussions with FDA and MHRA for COVID-19 and FDA Meeting on BLA Filing Sep 10, 2020 4:50pm EDT
U.K. MHRA Grants Meeting to CytoDyn to Discuss Fast Track Approval of Leronlimab for COVID-19 Patients Sep 02, 2020 4:01pm EDT
CytoDyn to Hold Conference Call on September 2 to Provide Update on Timelines for Multiple Regulatory and Clinical Initiatives Including COVID-19 Potential Approvals Aug 28, 2020 4:37pm EDT
CytoDyn Reaches Enrollment of 195 Patients in its Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms Aug 25, 2020 8:48pm EDT
After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.’s MHRA Accepts CytoDyn’s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms Aug 20, 2020 4:51am EDT
To Avoid Delay, the FDA Recommends CytoDyn Conduct Its Type A Meeting in Writing with FDA Response Goal Date of September 4 Aug 20, 2020 3:36am EDT
CytoDyn Announces Upcoming Retirement of Dr. David Welch from its Board of Directors Aug 19, 2020 2:44am EDT
CytoDyn Requests “Fast Track Approval” for COVID-19 Patients from U.K.’s Regulatory Agency MHRA based on its Top-line Report Showing Statistically Significant Endpoint, NEWS2 (p < 0.023) and Notable Safety Results Aug 19, 2020 1:25am EDT
CytoDyn Will Attempt to Duplicate Berlin and London Patients’ HIV Cure by Using Leronlimab During Bone Marrow Transplant for 5 HIV Patients Who also have Cancer Aug 17, 2020 6:15am EDT
